Analysts Set Expectations for Balchem Co.’s Q2 2025 Earnings (NASDAQ:BCPC)

Balchem Co. (NASDAQ:BCPC) – Equities research analysts at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for shares of Balchem in a report issued on Monday, May 6th. HC Wainwright analyst R. Selvaraju anticipates that the basic materials company will earn $1.04 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $170.00 price target on the stock. The consensus estimate for Balchem’s current full-year earnings is $4.10 per share. HC Wainwright also issued estimates for Balchem’s Q4 2025 earnings at $1.12 EPS.

Balchem (NASDAQ:BCPC) last posted its quarterly earnings results on Friday, February 16th. The basic materials company reported $0.95 earnings per share for the quarter, beating analysts’ consensus estimates of $0.93 by $0.02. The company had revenue of $228.70 million for the quarter, compared to the consensus estimate of $234.66 million. Balchem had a net margin of 12.35% and a return on equity of 11.03%. The firm’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same period last year, the company posted $0.66 EPS.

Separately, StockNews.com downgraded Balchem from a “buy” rating to a “hold” rating in a report on Thursday, April 25th.

Balchem Stock Performance

Shares of Balchem stock opened at $155.02 on Wednesday. The company’s 50 day moving average price is $150.94 and its two-hundred day moving average price is $141.39. The firm has a market capitalization of $5.03 billion, a P/E ratio of 43.79, a P/E/G ratio of 3.33 and a beta of 0.72. Balchem has a fifty-two week low of $110.74 and a fifty-two week high of $159.52. The company has a debt-to-equity ratio of 0.31, a current ratio of 2.61 and a quick ratio of 1.72.

Insider Activity at Balchem

In other Balchem news, CAO William A. Backus sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $154.73, for a total transaction of $2,320,950.00. Following the sale, the chief accounting officer now directly owns 12,914 shares of the company’s stock, valued at approximately $1,998,183.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CAO William A. Backus sold 7,000 shares of the firm’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $155.19, for a total transaction of $1,086,330.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,914 shares in the company, valued at $917,793.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO William A. Backus sold 15,000 shares of Balchem stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $154.73, for a total value of $2,320,950.00. Following the completion of the transaction, the chief accounting officer now directly owns 12,914 shares in the company, valued at $1,998,183.22. The disclosure for this sale can be found here. Insiders sold a total of 76,630 shares of company stock worth $11,843,249 in the last quarter. 1.77% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Signaturefd LLC increased its position in shares of Balchem by 123.0% during the fourth quarter. Signaturefd LLC now owns 165 shares of the basic materials company’s stock worth $25,000 after buying an additional 91 shares during the period. Principal Securities Inc. acquired a new stake in Balchem during the 4th quarter worth about $28,000. Operose Advisors LLC bought a new position in shares of Balchem in the 3rd quarter worth about $31,000. GAMMA Investing LLC bought a new position in shares of Balchem in the 4th quarter worth about $56,000. Finally, YHB Investment Advisors Inc. acquired a new position in shares of Balchem in the 1st quarter valued at about $69,000. Institutional investors own 87.91% of the company’s stock.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.